Losses shrink at Cure Pharmaceutical
Cure Pharmaceutical Co., an Oxnard-based drug delivery product company that owns the CBD brand Sera Labs, reported rising revenue and shrinking losses for the quarter ended June 30. Cure’s net loss for the second quarter of 2021 was $1.3 million, down from a loss of $13.4 million in the same quarter of 2020. Total revenue Read More →
Cure reports net loss, rising revenue in Q1
Oxnard-based Cure Pharmaceutical saw another spike in revenue in the first quarter of 2021, but net losses also continued to grow. Cure had $1.5 million in revenue in the quarter ended March 31, up 400% from the first quarter of 2020, according to the company’s earnings report, released May 17. The bulk of that growth Read More →
Cure Pharmaceutical navigates CBD acquisition, licensing dispute
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Revenues and losses both grew at Cure in 2020
Cure Pharmaceutical, an Oxnard company with a CBD products subsidiary, reported steep revenue growth but rising net losses in the fourth quarter and full year of 2020. In an annual statement released April 1, Cure reported revenue of $2.1 million in the final quarter of 2020, up 229% from the same quarter a year before. Read More →
Oxnard company to pursue therapeutic psychedelics
Oxnard-based Cure Pharmaceutical announced plans on March 16 to use its oral film technology to deliver LSD and other psychedelic substances to treat mental health disorders. Cure owns the CBD company Sera Labs, and Cure has used its dissolving thin film platform, Curefilm, to deliver CBD and other cannabis compounds. Cure has a license from Read More →
Cure closes $20M CBD acquisition
Cure Pharmaceutical, an Oxnard cannabis products manufacturer, has completed its $20 million cash-and-stock buyout of the CBD company Sera Labs, a deal Cure says will help it reach positive cash flow in around 18 months. Cure’s stock, which is traded on the over-the-counter markets, fell 3 percent following the announcement, closing at $1.29 per share Read More →
Oxnard’s Cure makes $20M buy of CBD firm
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
